Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 87pembrolizumab 82Magnetic Resonance Spectroscopy 46Radiotherapy, Intensity-Modulated 41Carboplatin 37Specimen Handling 36Cetuximab 36Radiotherapy 35Nivolumab 29Paclitaxel 24Platinum 23Radiation 22Docetaxel 22Gemcitabine 21Biopsy 211,2-diaminocyclohexaneplatinum II citrate 21Surveys and Questionnaires 17Fluorouracil 14Standard of Care 13toripalimab 12Taxes 11Cyclophosphamide 10cemiplimab 9atezolizumab 9X-Rays 9Surgical Procedures, Operative 9Ipilimumab 9Immunoglobulin G 9Drug Therapy 9Capecitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
penpulimab × Head & Neck × 90 days × Clear all
NCT05563480 2026-04-07

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
47 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡